person · Reporting owner

HENNEMAN JOHN B III

Disclosed activity across 7 companies

Tapewire entity: 36126
SEC CIK: 0001187572

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Anika Therapeutics, Inc.ANIK · Entity 6005	Director	June 18, 2026	June 23, 2026
Aprea Therapeutics, Inc.APRE · Entity 7948	Director	June 16, 2026	June 17, 2026
LUMOS PHARMA, INC.(NLNK) · Entity 85102	Chief Administrative Officer	October 01, 2018	October 02, 2018
Orthofix Medical Inc.OFIX · Entity 1975	Director	June 10, 2026	June 12, 2026
R1 RCM Holdco Inc.NONE · Entity 125898	Director	June 21, 2022	June 24, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Anika Therapeutics, Inc.

Report date June 18, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	65,273	Reported balance After 2026-06-18 transaction · row 1 1 source row Row 1 · 2026-06-18 · Grant · Acquired 10,402 · Balance 65,273 F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2027 annual meeting of the Company's stockholders or June 18, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2027 annual meeting of the Company's stockholders or June 18, 2027.

Aprea Therapeutics, Inc.

Report date June 16, 2026 · Filed June 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	13,364	Reported balance After 2026-06-16 transaction · row 1 1 source row Row 1 · 2026-06-16 · Grant · Acquired 3,135 · Balance 13,364 F1: These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.73 · Expires 2036-06-16	Direct	12,555	Reported balance After 2026-06-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-16 · Grant · Acquired 12,555 · Balance 12,555 F2: The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

Filing footnotes · ownership attribution and instrument terms

F1: These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

F2: The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

LUMOS PHARMA, INC.

Report date October 01, 2018 · Filed October 02, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	55,052	Reported balance After 2018-10-01 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2018-10-01 · Tax withholding · Disposed 2,484 · Balance 55,052 F1: Represents shares of Common Stock withheld by the Issuer in satisfaction of its tax withholding obligation with respect to the vesting of 10,198 previously reported restricted stock units ("RSUs") granted to the Reporting Person. F2: Includes 500 RSUs previously reported as holdings of the Reporting Person granted under the Issuer's 2009 Equity Incentive Plan (the "Plan"). The RSUs will vest, and shares will be delivered to the Reporting Person in one installment on January 2, 2019, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. F3: Includes 8,101 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in two successive annual installments with the next installment occurring on January 4, 2019, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of Common Stock withheld by the Issuer in satisfaction of its tax withholding obligation with respect to the vesting of 10,198 previously reported restricted stock units ("RSUs") granted to the Reporting Person.

F2: Includes 500 RSUs previously reported as holdings of the Reporting Person granted under the Issuer's 2009 Equity Incentive Plan (the "Plan"). The RSUs will vest, and shares will be delivered to the Reporting Person in one installment on January 2, 2019, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.

F3: Includes 8,101 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in two successive annual installments with the next installment occurring on January 4, 2019, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.

Orthofix Medical Inc.

Report date June 10, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	105,774	Reported balance After 2026-06-10 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-10 · Grant · Acquired 14,965 · Balance 105,774 F1: Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer. F2: Includes 48,347 previously reported deferred stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer.

F2: Includes 48,347 previously reported deferred stock units.

R1 RCM Holdco Inc.

Report date June 21, 2022 · Filed June 24, 2022

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-06-21 transaction · row 1 1 source row Row 1 · 2022-06-21 · Disposition to issuer · Disposed 54,751 · Balance 0 F1: On June 21, 2022, pursuant to the Transaction Agreement and Plan of Merger, dated as of January 9, 2022, by and among R1 RCM Holdco Inc. (f/k/a R1 RCM Inc.) (the "Company"), R1 RCM Inc. (f/k/a Project Roadrunner Parent Inc.) ("New R1"), Project Roadrunner Merger Sub Inc. ("R1 Merger Sub"), CoyCo 1, L.P., CoyCo 2, L.P. and certain other parties, R1 Merger Sub was merged with and into the Company, with the Company surviving as a direct, wholly owned subsidiary of New R1 (the "Reorganization"). F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.61 · Expires 2026-02-22	Direct	Reported balance After 2022-06-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-06-21 · Disposition to issuer · Disposed 405,111 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F3: Option was granted under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.53 · Expires 2026-04-01	Direct	Reported balance After 2022-06-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-06-21 · Disposition to issuer · Disposed 12,048 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2026-07-01	Direct	Reported balance After 2022-06-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-06-21 · Disposition to issuer · Disposed 15,385 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.42 · Expires 2026-10-03	Direct	Reported balance After 2022-06-21 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-06-21 · Disposition to issuer · Disposed 13,762 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.29 · Expires 2027-01-03	Direct	Reported balance After 2022-06-21 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-06-21 · Disposition to issuer · Disposed 14,098 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.08 · Expires 2027-04-03	Direct	Reported balance After 2022-06-21 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-06-21 · Disposition to issuer · Disposed 10,512 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.55 · Expires 2027-07-03	Direct	Reported balance After 2022-06-21 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-06-21 · Disposition to issuer · Disposed 9,678 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.76 · Expires 2027-10-02	Direct	Reported balance After 2022-06-21 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2022-06-21 · Disposition to issuer · Disposed 9,169 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.43 · Expires 2028-01-02	Direct	Reported balance After 2022-06-21 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2022-06-21 · Disposition to issuer · Disposed 7,697 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.07 · Expires 2028-04-02	Direct	Reported balance After 2022-06-21 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2022-06-21 · Disposition to issuer · Disposed 4,770 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.65 · Expires 2028-07-02	Direct	Reported balance After 2022-06-21 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2022-06-21 · Disposition to issuer · Disposed 3,871 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.01 · Expires 2028-10-01	Direct	Reported balance After 2022-06-21 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2022-06-21 · Disposition to issuer · Disposed 3,319 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.89 · Expires 2029-01-02	Direct	Reported balance After 2022-06-21 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2022-06-21 · Disposition to issuer · Disposed 4,285 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.57 · Expires 2029-04-01	Direct	Reported balance After 2022-06-21 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2022-06-21 · Disposition to issuer · Disposed 3,684 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.65 · Expires 2029-07-01	Direct	Reported balance After 2022-06-21 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2022-06-21 · Disposition to issuer · Disposed 2,846 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.05 · Expires 2029-10-01	Direct	Reported balance After 2022-06-21 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2022-06-21 · Disposition to issuer · Disposed 4,025 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.69 · Expires 2030-01-02	Direct	Reported balance After 2022-06-21 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2022-06-21 · Disposition to issuer · Disposed 2,851 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.41 · Expires 2030-04-01	Direct	Reported balance After 2022-06-21 transaction · row 19 Instrument identity requires review; Table II rows are not merged. 1 source row Row 19 · 2022-06-21 · Disposition to issuer · Disposed 4,542 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.75 · Expires 2030-05-28	Direct	Reported balance After 2022-06-21 transaction · row 20 Instrument identity requires review; Table II rows are not merged. 1 source row Row 20 · 2022-06-21 · Disposition to issuer · Disposed 30,813 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F3: Option was granted under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.78 · Expires 2030-07-01	Direct	Reported balance After 2022-06-21 transaction · row 21 Instrument identity requires review; Table II rows are not merged. 1 source row Row 21 · 2022-06-21 · Disposition to issuer · Disposed 3,249 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.54 · Expires 2030-10-01	Direct	Reported balance After 2022-06-21 transaction · row 22 Instrument identity requires review; Table II rows are not merged. 1 source row Row 22 · 2022-06-21 · Disposition to issuer · Disposed 2,186 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.49 · Expires 2031-01-04	Direct	Reported balance After 2022-06-21 transaction · row 23 Instrument identity requires review; Table II rows are not merged. 1 source row Row 23 · 2022-06-21 · Disposition to issuer · Disposed 1,625 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.98 · Expires 2031-04-01	Direct	Reported balance After 2022-06-21 transaction · row 24 Instrument identity requires review; Table II rows are not merged. 1 source row Row 24 · 2022-06-21 · Disposition to issuer · Disposed 1,490 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.46 · Expires 2031-07-01	Direct	Reported balance After 2022-06-21 transaction · row 25 Instrument identity requires review; Table II rows are not merged. 1 source row Row 25 · 2022-06-21 · Disposition to issuer · Disposed 1,660 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F5: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option will vest in one installment on July 1, 2022.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.57 · Expires 2031-10-01	Direct	Reported balance After 2022-06-21 transaction · row 26 Instrument identity requires review; Table II rows are not merged. 1 source row Row 26 · 2022-06-21 · Disposition to issuer · Disposed 1,649 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F6: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option will vest in one installment on October 1, 2022.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.70 · Expires 2032-01-03	Direct	Reported balance After 2022-06-21 transaction · row 27 Instrument identity requires review; Table II rows are not merged. 1 source row Row 27 · 2022-06-21 · Disposition to issuer · Disposed 1,424 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F7: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option will vest in one installment on January 3, 2023.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.69 · Expires 2032-04-01	Direct	Reported balance After 2022-06-21 transaction · row 28 Instrument identity requires review; Table II rows are not merged. 1 source row Row 28 · 2022-06-21 · Disposition to issuer · Disposed 1,965 · Balance 0 F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F8: Option was granted in lieu of retainer fees of $22,500 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option will vest in one installment on April 1, 2023.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-06-21 transaction · row 29 Instrument identity requires review; Table II rows are not merged. 1 source row Row 29 · 2022-06-21 · Disposition to issuer · Disposed 6,039 · Balance 0 F9: Each RSU represents a contingent right to receive one share of the Company's common stock. F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization. F10: The RSUs will vest in one annual installment on May 27, 2023.

Filing footnotes · ownership attribution and instrument terms

F1: On June 21, 2022, pursuant to the Transaction Agreement and Plan of Merger, dated as of January 9, 2022, by and among R1 RCM Holdco Inc. (f/k/a R1 RCM Inc.) (the "Company"), R1 RCM Inc. (f/k/a Project Roadrunner Parent Inc.) ("New R1"), Project Roadrunner Merger Sub Inc. ("R1 Merger Sub"), CoyCo 1, L.P., CoyCo 2, L.P. and certain other parties, R1 Merger Sub was merged with and into the Company, with the Company surviving as a direct, wholly owned subsidiary of New R1 (the "Reorganization").

F2: Upon consummation of the Reorganization, each share of the Company's common stock issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding share of common stock of New R1 and the Company's stockholders became stockholders of New R1. In addition, each restricted stock unit ("RSU") and option to purchase shares of common stock of the Company issued and outstanding immediately prior to the Reorganization was automatically exchanged into an equivalent corresponding RSU or option to purchase shares of common stock of New R1, subject to the same terms and conditions (including applicable vesting terms) as were applicable to RSUs or options to purchase shares immediately prior to the consummation of the Reorganization.

F3: Option was granted under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.

F4: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option is fully vested.

F5: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option will vest in one installment on July 1, 2022.

F6: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option will vest in one installment on October 1, 2022.

F7: Option was granted in lieu of retainer fees of $15,000 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option will vest in one installment on January 3, 2023.

F8: Option was granted in lieu of retainer fees of $22,500 under a stock incentive plan, in a transaction exempt under Rule 16(b)-3. The option will vest in one installment on April 1, 2023.

F9: Each RSU represents a contingent right to receive one share of the Company's common stock.

F10: The RSUs will vest in one annual installment on May 27, 2023.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

R1 RCM Inc. /DE

Report date November 19, 2024 · Filed November 19, 2024

Section 16 reporting ended · disclosed 2024-11-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2024-11-19 transaction · row 1 1 source row Row 1 · 2024-11-19 · Disposition to issuer · Disposed 87,765 · Balance 0 F1: Pursuant to and in connection with the transactions contemplated by that certain Agreement and Plan of Merger (the "Merger Agreement"), dated July 31, 2024, by and among the Issuer, Raven Acquisition Holdings, LLC ("Parent") and Project Raven Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), at the time of the Merger (the "Effective Time") the reported securities were disposed of, with 72,114 shares of the Issuer's common stock, par value $0.01 per share (the "Common Stock"), cancelled and converted into the right to receive $14.30 per share in cash without interest (the "Merger Consideration"). F2: Represents 15,651 shares of Common Stock of the Issuer underlying restricted stock units ("RSUs") of the Issuer which, pursuant to the Merger Agreement, were, at the Effective Time, automatically cancelled and converted into the right to receive an amount in cash (without interest and subject to applicable withholding taxes) equal to the product of (a) the number of shares of Common Stock subject to such RSUs as of immediately prior to the Effective Time and (b) the Merger Consideration.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-11-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-11-19 · Disposition to issuer · Disposed 515,715 · Balance 0 F3: Each outstanding option to purchase Common Stock ("Options") held by the Reporting Person that was outstanding and unexercised immediately prior to or upon the Effective Time, whether vested or unvested, was, at the Effective Time, automatically cancelled and converted into the right to receive an amount in cash (without interest and subject to applicable withholding taxes) equal to the product of (a) the number of shares of Common Stock subject to such Option and (b) the amount by which the Merger Consideration exceeds the applicable per share exercise price of such Option, with any Options that have a per share exercise price equal to or exceeding the Merger Consideration being cancelled for no consideration as of the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to and in connection with the transactions contemplated by that certain Agreement and Plan of Merger (the "Merger Agreement"), dated July 31, 2024, by and among the Issuer, Raven Acquisition Holdings, LLC ("Parent") and Project Raven Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), at the time of the Merger (the "Effective Time") the reported securities were disposed of, with 72,114 shares of the Issuer's common stock, par value $0.01 per share (the "Common Stock"), cancelled and converted into the right to receive $14.30 per share in cash without interest (the "Merger Consideration").

F2: Represents 15,651 shares of Common Stock of the Issuer underlying restricted stock units ("RSUs") of the Issuer which, pursuant to the Merger Agreement, were, at the Effective Time, automatically cancelled and converted into the right to receive an amount in cash (without interest and subject to applicable withholding taxes) equal to the product of (a) the number of shares of Common Stock subject to such RSUs as of immediately prior to the Effective Time and (b) the Merger Consideration.

F3: Each outstanding option to purchase Common Stock ("Options") held by the Reporting Person that was outstanding and unexercised immediately prior to or upon the Effective Time, whether vested or unvested, was, at the Effective Time, automatically cancelled and converted into the right to receive an amount in cash (without interest and subject to applicable withholding taxes) equal to the product of (a) the number of shares of Common Stock subject to such Option and (b) the amount by which the Merger Consideration exceeds the applicable per share exercise price of such Option, with any Options that have a per share exercise price equal to or exceeding the Merger Consideration being cancelled for no consideration as of the Effective Time.

SeaSpine Holdings Corp

Report date January 05, 2023 · Filed January 10, 2023

Section 16 reporting ended · disclosed 2023-01-10. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-01-05 transaction · row 1 1 source row Row 1 · 2023-01-05 · Disposition to issuer · Disposed 82,654 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger by and among the issuer, SeaSpine Holdings Corporation, which became effective on January 5, 2023, in exchange for 34,408 Orthofix MedicalInc. ("Orthofix") ordinary shares having a market value of $22.76 per share at the effective time of the merger.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.68 · Expires 2025-08-01	Direct	Reported balance After 2023-01-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-01-05 · Disposition to issuer · Disposed 58,559 · Balance 0 F3: This option was assumed by Orthofix in the merger and replaced with an option to purchase 24,378 shares of Orthofix at a price of $37.67 per share. F2: The option vests as to 25% of the underlying shares on November 1, 2015 and the remaining 75% in three equal quarterly installments thereafter.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.18 · Expires 2026-01-01	Direct	Reported balance After 2023-01-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-01-05 · Disposition to issuer · Disposed 3,858 · Balance 0 F5: This option was assumed by Orthofix in the merger and replaced with an option to purchase 1,606 shares of Orthofix at a price of $41.27 per share. F4: The option vests as to 50% of the underlying shares on February 1, 2016 and as to 25% of the underlying shares on each of May 1, 2016 and August 1, 2016.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.99 · Expires 2026-06-07	Direct	Reported balance After 2023-01-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-01-05 · Disposition to issuer · Disposed 13,920 · Balance 0 F7: This option was assumed by Orthofix in the merger and replaced with an option to purchase 5,794 shares of Orthofix at a price of $24.00 per share. F6: The option vests in four equal installments on each of September 7, 2016, December 7, 2016, March 7, 2017 and June 7, 2017.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger by and among the issuer, SeaSpine Holdings Corporation, which became effective on January 5, 2023, in exchange for 34,408 Orthofix MedicalInc. ("Orthofix") ordinary shares having a market value of $22.76 per share at the effective time of the merger.

F2: The option vests as to 25% of the underlying shares on November 1, 2015 and the remaining 75% in three equal quarterly installments thereafter.

F3: This option was assumed by Orthofix in the merger and replaced with an option to purchase 24,378 shares of Orthofix at a price of $37.67 per share.

F4: The option vests as to 50% of the underlying shares on February 1, 2016 and as to 25% of the underlying shares on each of May 1, 2016 and August 1, 2016.

F5: This option was assumed by Orthofix in the merger and replaced with an option to purchase 1,606 shares of Orthofix at a price of $41.27 per share.

F6: The option vests in four equal installments on each of September 7, 2016, December 7, 2016, March 7, 2017 and June 7, 2017.

F7: This option was assumed by Orthofix in the merger and replaced with an option to purchase 5,794 shares of Orthofix at a price of $24.00 per share.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 01, 2021 Filed Jul 1, 2021 23:20 UTC	R1 RCM Holdco Inc. RCM · Entity 125898	GrantDirector Stock Option (right to buy) · Derivative	1,660	$9.04 Strike: $22.46	$15,004.74	Disclosure SEC source: 0001628280-21-013388 · wf-form4_162518157245265.xml · derivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,660 Underlying: Common Stock · 1,660 shares Expires 2031-07-01 F1 · price: This option was issued to the reporting person pursuant to the R1 RCM Inc. director compensation plan in lieu of retainer fees of $15,000. Read SEC document
June 30, 2021 Filed Jul 1, 2021 23:09 UTC	Aprea Therapeutics, Inc. APRE · Entity 7948	GrantStock Option (Right to Buy) · Derivative	22,750	$0.00 Strike: $4.88	$0.00	Disclosure SEC source: 0001567619-21-012875 · doc1.xml · derivative · entry 2 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,750 Underlying: Common Stock · 22,750 shares Expires 2031-06-30 F2 · derivative.exercise_date: The option vests in full on June 30, 2022, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document
June 30, 2021 Filed Jul 1, 2021 23:09 UTC	Aprea Therapeutics, Inc. APRE · Entity 7948	GrantCommon Stock	4,610	$0.00	$0.00	Disclosure SEC source: 0001567619-21-012875 · doc1.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,610 F1 · shares: These shares represent restricted stock units which were granted on June 30, 2021, and which will vest and be settled in common stock on June 30, 2022, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document
June 16, 2021 Filed Jun 21, 2021 20:15 UTC	Anika Therapeutics, Inc. ANIK · Entity 6005	GrantCommon Stock	4,172	$0.00	$0.00	Disclosure SEC source: 0001171843-21-004426 · ownership.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,482 F1 · shares: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on the earlier of the 2022 annual meeting of the Company's stockholders or June 16, 2022. Read SEC document
June 02, 2021 Filed Jun 4, 2021 20:17 UTC	SeaSpine Holdings Corp SPNE · Entity 120832	GrantCommon Stock	6,253	$0.00	$0.00	Disclosure SEC source: 0001637761-21-000130 · wf-form4_162283783411079.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,711 F1 · shares: The restricted stock award vests in full on June 2, 2022, subject to the Reporting Person not experiencing a termination of service prior to such date. In addition, if the Reporting Person stands for reelection to the board of directors of SeaSpine Holdings Corporation ("SeaSpine") at an annual meeting of stockholders but is not reelected to the board at such annual meeting, the award will vest in full on the date of such annual meeting. Read SEC document
May 21, 2021 Filed May 24, 2021 21:33 UTC	R1 RCM Holdco Inc. RCM · Entity 125898	GrantRestricted Stock Units · Derivative	5,151	$0.00	$0.00	Disclosure SEC source: 0001628280-21-011001 · wf-form4_162189199541722.xml · derivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,151 Underlying: Common Stock · 5,151 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units will vest in one annual installment on May 21, 2022. F2 · derivative.expiration_date: The restricted stock units will vest in one annual installment on May 21, 2022. Read SEC document
May 18, 2021 Filed May 20, 2021 20:39 UTC	Anika Therapeutics, Inc. ANIK · Entity 6005	PurchaseCommon Stock	2,000	$42.86	$85,720.00	Disclosure SEC source: 0001171843-21-003679 · ownership.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,310 F1 · price: On May 18, 2021, Mr. Henneman purchased 2,000 shares in multiple trades ranging from $42.63 to $42.98. The price reported above reflects the weighted average purchase price. Mr. Henneman undertakes to provide the Securities and Exchange Commission staff, the issuer, or any security holder, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document
April 01, 2021 Filed Apr 2, 2021 20:40 UTC	R1 RCM Holdco Inc. RCM · Entity 125898	GrantDirector Stock Option (right to buy) · Derivative	1,490	$10.07 Strike: $24.98	$15,004.30	Disclosure SEC source: 0001628280-21-006483 · wf-form4_161739596760534.xml · derivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,490 Underlying: Common Stock · 1,490 shares Expires 2031-04-01 F1 · price: This option was issued to the reporting person pursuant to the R1 RCM Inc. director compensation plan in lieu of retainer fees of $15,000. Read SEC document
January 04, 2021 Filed Jan 6, 2021 01:17 UTC	R1 RCM Holdco Inc. RCM · Entity 125898	GrantDirector Stock Option (right to buy) · Derivative	1,625	$9.24 Strike: $23.49	$15,006.88	Disclosure SEC source: 0001628280-21-000130 · wf-form4_160989583269050.xml · derivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,625 Underlying: Common Stock · 1,625 shares Expires 2031-01-04 F1 · price: This option was issued to the reporting person pursuant to the R1 RCM Inc. director compensation plan in lieu of retainer fees of $15,000. Read SEC document
October 01, 2020 Filed Oct 2, 2020 22:40 UTC	R1 RCM Holdco Inc. RCM · Entity 125898	GrantDirector Stock Option (right to buy) · Derivative	2,186	$6.86 Strike: $17.54	$15,002.52	Disclosure SEC source: 0001628280-20-014217 · wf-form4_160167840260080.xml · derivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,186 Underlying: Common Stock · 2,186 shares Expires 2030-10-01 F1 · price: This option was issued to the reporting person pursuant to the R1 RCM Inc. director compensation plan in lieu of retainer fees of $15,000. Read SEC document
September 03, 2020 Filed Sep 8, 2020 22:12 UTC	Anika Therapeutics, Inc. ANIK · Entity 6005	GrantCommon Stock	9,310	$0.00	$0.00	Disclosure SEC source: 0001171843-20-006336 · ownership.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,310 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents the contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in three equal annual installments immediately prior to the Anika Therapeutics, Inc., Annual Meetings of Stockholders beginning in 2021, 2022, and 2023. Read SEC document
August 05, 2020 Filed Aug 5, 2020 23:39 UTC	SeaSpine Holdings Corp SPNE · Entity 120832	SaleCommon Stock	10,000	$15.00	$150,000.00	Disclosure SEC source: 0001637761-20-000109 · wf-form4_159667076961599.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,458 F1 · price: The transaction reported was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document
July 01, 2020 Filed Jul 2, 2020 20:41 UTC	R1 RCM Holdco Inc. RCM · Entity 125898	GrantDirector Stock Option (right to buy) · Derivative	3,249	$4.62 Strike: $11.78	$15,003.88	Disclosure SEC source: 0001628280-20-010170 · wf-form4_159372248000496.xml · derivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,249 Underlying: Common Stock · 3,249 shares Expires 2030-07-01 F1 · price: This option was issued to the reporting person pursuant to the R1 RCM Inc. director compensation plan in lieu of retainer fees of $15,000. Read SEC document
June 30, 2020 Filed Jul 1, 2020 22:08 UTC	Aprea Therapeutics, Inc. APRE · Entity 7948	GrantStock Option (right to Buy) · Derivative	5,600	$0.00 Strike: $38.78	$0.00	Disclosure SEC source: 0000905148-20-000752 · form4.xml · derivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,600 Underlying: Common Stock · 5,600 shares Expires 2030-06-30 F1 · derivative.exercise_date: The option vests in full on June 30, 2021 subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document
June 03, 2020 Filed Jun 5, 2020 23:42 UTC	SeaSpine Holdings Corp SPNE · Entity 120832	GrantCommon Stock	8,488	$0.00	$0.00	Disclosure SEC source: 0001637761-20-000075 · wf-form4_159140050453147.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,458 F1 · shares: The restricted stock award vests in full on June 3, 2021, subject to the Reporting Person not experiencing a termination of service prior to such date. In addition, if the Reporting Person stands for reelection to the board of directors of SeaSpine Holdings Corporation ("SeaSpine") at an annual meeting of stockholders but is not reelected to the board at such annual meeting, the award will vest in full on the date of such annual meeting. Read SEC document
May 28, 2020 Filed May 29, 2020 20:29 UTC	R1 RCM Holdco Inc. RCM · Entity 125898	GrantDirector Stock Option (right to buy) · Derivative	30,813	$0.00 Strike: $10.75	$0.00	Disclosure SEC source: 0001628280-20-008653 · wf-form4_159078415429167.xml · derivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,813 Underlying: Common Stock · 30,813 shares Expires 2030-05-28 Read SEC document
April 01, 2020 Filed Apr 3, 2020 20:45 UTC	R1 RCM Holdco Inc. RCM · Entity 125898	GrantDirector Stock Option (right to buy) · Derivative	4,542	$3.30 Strike: $8.41	$15,002.23	Disclosure SEC source: 0001628280-20-004595 · wf-form4_158594671446295.xml · derivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,542 Underlying: Common Stock · 4,542 shares Expires 2030-04-01 F1 · price: This option was issued to the reporting person pursuant to the R1 RCM Inc. director compensation plan in lieu of retainer fees of $15,000. Read SEC document
January 02, 2020 Filed Jan 3, 2020 21:37 UTC	R1 RCM Holdco Inc. RCM · Entity 125898	GrantDirector Stock Option (right to buy) · Derivative	2,851	$5.26 Strike: $12.69	$14,996.26	Disclosure SEC source: 0001628280-20-000101 · wf-form4_157808741540227.xml · derivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,851 Underlying: Common Stock · 2,851 shares Expires 2030-01-02 F1 · price: This option was issued to the reporting person pursuant to the R1 RCM Inc. director compensation plan in lieu of retainer fees of $15,000. Read SEC document
December 24, 2019 Filed Jan 17, 2020 22:09 UTC	R1 RCM Holdco Inc. RCM · Entity 125898	GiftCommon Stock	400	$0.00	$0.00	Disclosure SEC source: 0001628280-20-000391 · wf-form5_157929897627122.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,600 Read SEC document
October 07, 2019 Filed Oct 7, 2019 23:23 UTC	Aprea Therapeutics, Inc. APRE · Entity 7948	GrantStock Option (right to Buy) · Derivative	18,407	$0.00 Strike: $15.00	$0.00	Disclosure SEC source: 0001140361-19-018079 · form4.xml · derivative · entry 2 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,407 Underlying: Common Stock · 18,407 shares Expires 2029-10-02 F1 · derivative.exercise_date: Twenty-five percent of these options vest on October 2, 2020, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document
October 07, 2019 Filed Oct 7, 2019 23:23 UTC	Aprea Therapeutics, Inc. APRE · Entity 7948	PurchaseCommon Stock	5,000	$15.00	$75,000.00	Disclosure SEC source: 0001140361-19-018079 · form4.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document
October 01, 2019 Filed Oct 3, 2019 21:01 UTC	R1 RCM Holdco Inc. RCM · Entity 125898	GrantDirector Stock Option (right to buy) · Derivative	4,025	$3.73 Strike: $9.05	$15,013.25	Disclosure SEC source: 0001628280-19-012138 · wf-form4_157013645214476.xml · derivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,025 Underlying: Common Stock · 4,025 shares Expires 2029-10-01 F1 · price: This option was issued to the reporting person pursuant to the R1 RCM Inc. director compensation plan in lieu of retainer fees of $15,000. Read SEC document
July 01, 2019 Filed Jul 2, 2019 21:49 UTC	R1 RCM Holdco Inc. RCM · Entity 125898	GrantDirector Stock Option (right to buy) · Derivative	2,846	$5.27 Strike: $12.65	$14,998.42	Disclosure SEC source: 0001628280-19-008545 · wf-form4_156210412430923.xml · derivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,846 Underlying: Common Stock · 2,846 shares Expires 2029-07-01 F1 · price: This option was issued to the reporting person pursuant to the R1 RCM Inc. director compensation plan in lieu of retainer fees of $15,000. Read SEC document
May 29, 2019 Filed May 31, 2019 20:13 UTC	SeaSpine Holdings Corp SPNE · Entity 120832	GrantCommon Stock	7,262	$0.00	$0.00	Disclosure SEC source: 0001637761-19-000078 · wf-form4_155933361894327.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,970 F1 · shares: The restricted stock award vests in full on May 29, 2020, subject to the Reporting Person not experiencing a termination of service prior to such date. In addition, if the Reporting Person stands for reelection to the board of directors of SeaSpine Holdings Corporation ("SeaSpine") at an annual meeting of stockholders but is not reelected to the board at such annual meeting, the award will vest in full on the date of such annual meeting. Read SEC document
April 01, 2019 Filed Apr 2, 2019 22:56 UTC	R1 RCM Holdco Inc. RCM · Entity 125898	GrantDirector Stock Option (right to buy) · Derivative	3,684	$4.07 Strike: $9.57	$14,993.88	Disclosure SEC source: 0001628280-19-003789 · wf-form4_155424574647400.xml · derivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,684 Underlying: Common Stock · 3,684 shares Expires 2029-04-01 F1 · price: This option was issued to the reporting person pursuant to the R1 RCM Inc. director compensation plan in lieu of retainer fees of $15,000. Read SEC document
January 02, 2019 Filed Jan 3, 2019 22:29 UTC	R1 RCM Holdco Inc. RCM · Entity 125898	GrantDirector Stock Option (right to buy) · Derivative	4,285	$3.50 Strike: $7.89	$14,997.50	Disclosure SEC source: 0001628280-19-000087 · wf-form4_154655457959450.xml · derivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,285 Underlying: Common Stock · 4,285 shares Expires 2029-01-02 F1 · price: This option was issued to the reporting person pursuant to the R1 RCM Inc. director compensation plan in lieu of retainer fees of $15,000. Read SEC document
October 01, 2018 Filed Oct 2, 2018 17:22 UTC	LUMOS PHARMA, INC. (NLNK) · Entity 85102	Tax withholdingCommon Stock	2,484	$2.28	$5,663.52	Disclosure SEC source: 0001126234-18-000127 · wf-form4_153851533449364.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,052 F1 · shares: Represents shares of Common Stock withheld by the Issuer in satisfaction of its tax withholding obligation with respect to the vesting of 10,198 previously reported restricted stock units ("RSUs") granted to the Reporting Person. F2 · balance_after: Includes 500 RSUs previously reported as holdings of the Reporting Person granted under the Issuer's 2009 Equity Incentive Plan (the "Plan"). The RSUs will vest, and shares will be delivered to the Reporting Person in one installment on January 2, 2019, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. F3 · balance_after: Includes 8,101 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in two successive annual installments with the next installment occurring on January 4, 2019, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. Read SEC document
October 01, 2018 Filed Oct 3, 2018 12:47 UTC	R1 RCM Holdco Inc. RCM · Entity 125898	GrantDirector Stock Option (right to buy) · Derivative	3,319	$4.52 Strike: $10.01	$15,001.88	Disclosure SEC source: 0001628280-18-012236 · wf-form4_153857080599291.xml · derivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,319 Underlying: Common Stock · 3,319 shares Expires 2028-10-01 F1 · price: This option was issued to the reporting person pursuant to the R1 RCM Inc. director compensation plan in lieu of retainer fees of $15,000. Read SEC document
August 29, 2018 Filed Aug 29, 2018 22:03 UTC	SeaSpine Holdings Corp SPNE · Entity 120832	SaleCommon Stock	3,407	$14.65	$49,912.55	Disclosure SEC source: 0001637761-18-000129 · wf-form4_153558021097767.xml · nonDerivative · entry 3 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,708 F3 · price: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from not less than $14.61 to not more than $14.76. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
August 28, 2018 Filed Aug 29, 2018 22:03 UTC	SeaSpine Holdings Corp SPNE · Entity 120832	SaleCommon Stock	2,029	$14.65	$29,724.85	Disclosure SEC source: 0001637761-18-000129 · wf-form4_153558021097767.xml · nonDerivative · entry 2 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,115 F2 · price: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from not less than $14.60 to not more than $14.76. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
August 27, 2018 Filed Aug 29, 2018 22:03 UTC	SeaSpine Holdings Corp SPNE · Entity 120832	SaleCommon Stock	4,564	$14.72	$67,182.08	Disclosure SEC source: 0001637761-18-000129 · wf-form4_153558021097767.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,144 F1 · price: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from not less than $14.60 to not more than $14.86. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
July 02, 2018 Filed Jul 3, 2018 21:54 UTC	R1 RCM Holdco Inc. RCM · Entity 125898	GrantDirector Stock Option (right to buy) · Derivative	3,871	$3.88 Strike: $8.65	$15,000.13	Disclosure SEC source: 0001628280-18-009087 · wf-form4_153065485967270.xml · derivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,871 Underlying: Common Stock · 3,871 shares Expires 2028-07-02 F1 · price: This option was issued to the reporting person pursuant to the R1 RCM Inc. director compensation plan in lieu of retainer fees of $15,000. Read SEC document
June 13, 2018 Filed Jun 13, 2018 23:50 UTC	SeaSpine Holdings Corp SPNE · Entity 120832	Exercise / conversionStock Option (right to buy · Derivative	17,398	$0.00 Strike: $12.44	$0.00	Disclosure SEC source: 0001637761-18-000100 · wf-form4_152893380242387.xml · derivative · entry 2 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,398 shares Expires 2018-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 13, 2018 Filed Jun 13, 2018 23:50 UTC	SeaSpine Holdings Corp SPNE · Entity 120832	Exercise / conversionCommon Stock	17,398	$12.44	$216,431.12	Disclosure SEC source: 0001637761-18-000100 · wf-form4_152893380242387.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 30, 2018 Filed May 31, 2018 20:50 UTC	SeaSpine Holdings Corp SPNE · Entity 120832	GrantCommon Stock	4,429	$0.00	$0.00	Disclosure SEC source: 0001637761-18-000093 · wf-form4_152779982193094.xml · nonDerivative · entry 2 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,310 F2 · shares: The restricted stock award vests as to 25% of the shares subject to the award on the last day of each three-month period of the Reporting Person's continuous service on SeaSpine's board of directors following May 30, 2018. F3 · balance_after: On July 1, 2015, Integra LifeSciences Holdings Corporation ("Integra") distributed 100% of the shares of common stock of SeaSpine that it owned to Integra stockholders of record as of the close of businesson June 19, 2015. The distribution was made to the stockholders of Integra on a pro rata basis by means of a share dividend. Integra distributed to its stockholders one share of SeaSpine common stock for everythree shares of Integra common stock held by stockholders of Integra as of the close of business on June 19, 2015. The distribution of SeaSpine shares was exempt from Section 16 of the Exchange Act by Rule16a-9. Includes 8,893 shares of SeaSpine issued to the Reporting Person pursuant to the distribution in respect of shares of Integra held by him prior to the distribution. Read SEC document
May 30, 2018 Filed May 31, 2018 20:50 UTC	SeaSpine Holdings Corp SPNE · Entity 120832	GrantCommon Stock	8,857	$0.00	$0.00	Disclosure SEC source: 0001637761-18-000093 · wf-form4_152779982193094.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,881 F1 · shares: The restricted stock award vests in full on May 30, 2019, subject to the Reporting Person not experiencing a termination of service prior to such date. In addition, if the Reporting Person stands for reelection to the board of directors of SeaSpine Holdings Corporation ("SeaSpine") at an annual meeting of stockholders but is not reelected to the board at such annual meeting, the award will vest in full on the date of such annual meeting. Read SEC document
April 02, 2018 Filed Apr 3, 2018 23:11 UTC	R1 RCM Holdco Inc. RCM · Entity 125898	GrantDirector Stock Option (right to buy) · Derivative	4,770	$3.15 Strike: $7.07	$15,001.65	Disclosure SEC source: 0001628280-18-003974 · wf-form4_152279705205994.xml · derivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,770 Underlying: Common Stock · 4,770 shares Expires 2028-04-02 F1 · price: This option was issued to the reporting person pursuant to the R1 RCM Inc. director compensation plan in lieu of retainer fees of $15,000. Read SEC document
March 09, 2018 Filed Mar 13, 2018 17:52 UTC	LUMOS PHARMA, INC. (NLNK) · Entity 85102	GrantStock Option (Right to Buy) · Derivative	122,000	$0.00 Strike: $7.85	$0.00	Disclosure SEC source: 0001126234-18-000042 · wf-form4_152097792686052.xml · derivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,000 Underlying: Common Stock · 122,000 shares Expires not disclosed F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2009 Equity Incentive Plan (the "Plan") on March 9, 2018 (the "Date of Grant"). 50% of the option vests and becomes exercisable in a series of 48 successive equal monthly installments beginning on April 1, 2018, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. The option expires ten years after the Date of Grant. F2 · derivative.exercise_date: The remaining 50% of the stock options vest and become exercisable as follows: (a) 25% of such shares shall vest as to 8.33%, 8.33% and 8.34% on the 1st day of the month following an increase of closing share price on Nasdaq Stock Market by at least 33.33%, 66.66% and 100%, respectively, above the exercise price of the options when measured over 30 consecutive calendar days, provided such increase occurs within four years of the Date of Grant, otherwise such options shall be cancelled; (b) 12.50% of such shares shall vest on the 1st day of the month following the hiring of a new senior operations executive to oversee the Company's chemistry and manufacturing control ("CMC") activities and clinical trials; and (c) the remaining 12.50% of such shares shall vest on the 1st day of the month following completion of a CMC formulation for indoximod for adult patients and completion of a CMC plan for a pediatric formulation of indoximod, the completion of each to be determined by the Board. F3 · derivative.expiration_date: Unless otherwise disclosed, the option expires ten years after the date of grant. Read SEC document
January 04, 2018 Filed Jan 4, 2018 19:01 UTC	LUMOS PHARMA, INC. (NLNK) · Entity 85102	Tax withholdingCommon Stock	1,323	$10.06	$13,309.38	Disclosure SEC source: 0001126234-18-000012 · wf-form4_151511045983562.xml · nonDerivative · entry 2 HENNEMAN JOHN B III · CIK 0001187572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,536 F7 · shares: Represents shares of Common Stock withheld by the Issuer in satisfaction of its tax withholding obligation with respect to the vesting of 4,050 previously reported RSUs granted to the Reporting Person. F2 · balance_after: Includes 10,198 RSUs previously reported as holdings of the Reporting Person granted under the Issuer's 2009 Equity Incentive Plan (the "Plan"). The RSUs will vest, and shares will be delivered to the Reporting Person in one installment on October 1, 2018, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. F3 · balance_after: Includes 500 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in one installment on January 2, 2019, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. F4 · balance_after: Includes 8,101 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in two successive annual installments with the next installment occurring on January 4, 2019, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. F5 · balance_after: Includes 2,100 shares acquired under the NewLink Genetics Corporation 2010 Employee Stock Purchase Plan on June 30, 2017. F6 · balance_after: Includes 379 shares acquired under the NewLink Genetics Corporation 2010 Employee Stock Purchase Plan on December 31, 2017. Read SEC document
January 02, 2018 Filed Jan 4, 2018 00:07 UTC	R1 RCM Holdco Inc. RCM · Entity 125898	GrantDirector Stock Option (right to buy) · Derivative	7,697	$1.95 Strike: $4.43	$15,009.15	Disclosure SEC source: 0001472595-18-000001 · wf-form4_151502440854885.xml · derivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,697 Underlying: Common Stock · 7,697 shares Expires 2028-01-02 F1 · price: This option was issued to the reporting person pursuant to the R1 RCM Inc. director compensation plan in lieu of retainer fees of $15,000. Read SEC document
January 02, 2018 Filed Jan 4, 2018 19:01 UTC	LUMOS PHARMA, INC. (NLNK) · Entity 85102	Tax withholdingCommon Stock	164	$8.47	$1,389.08	Disclosure SEC source: 0001126234-18-000012 · wf-form4_151511045983562.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,859 F1 · shares: Represents shares of Common Stock withheld by the Issuer in satisfaction of its tax withholding obligation with respect to the vesting of 500 previously reported restricted stock units ("RSUs") granted to the Reporting Person. F2 · balance_after: Includes 10,198 RSUs previously reported as holdings of the Reporting Person granted under the Issuer's 2009 Equity Incentive Plan (the "Plan"). The RSUs will vest, and shares will be delivered to the Reporting Person in one installment on October 1, 2018, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. F3 · balance_after: Includes 500 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in one installment on January 2, 2019, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. F4 · balance_after: Includes 8,101 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in two successive annual installments with the next installment occurring on January 4, 2019, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. F5 · balance_after: Includes 2,100 shares acquired under the NewLink Genetics Corporation 2010 Employee Stock Purchase Plan on June 30, 2017. F6 · balance_after: Includes 379 shares acquired under the NewLink Genetics Corporation 2010 Employee Stock Purchase Plan on December 31, 2017. Read SEC document
October 02, 2017 Filed Oct 3, 2017 21:31 UTC	R1 RCM Holdco Inc. RCM · Entity 125898	GrantDirector Stock Option (right to buy) · Derivative	9,169	$1.64 Strike: $3.76	$15,037.16	Disclosure SEC source: 0001472595-17-000109 · wf-form4_150706625474108.xml · derivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,169 Underlying: Common Stock · 9,169 shares Expires 2027-10-02 F1 · price: This option was issued to the reporting person pursuant to the R1 RCM Inc. director compensation plan in lieu of retainer fees of $15,000. Read SEC document
October 01, 2017 Filed Oct 2, 2017 07:08 UTC	LUMOS PHARMA, INC. (NLNK) · Entity 85102	Tax withholdingCommon Stock	2,789	$10.18	$28,392.02	Disclosure SEC source: 0001126234-17-000087 · wf-form4_150694249547449.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,544 F1 · shares: Represents shares of Common Stock withheld by the Issuer in satisfaction of its tax withholding obligation with respect to the vesting of 10,197 previously reported restricted stock units ("RSUs") granted to the Reporting Person. F2 · balance_after: Includes 10,198 RSUs previously reported as holdings of the Reporting Person granted under the Issuer's 2009 Equity Incentive Plan (the "Plan"). The RSUs will vest, and shares will be delivered to the Reporting Person in one installment on October 1, 2018, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. F3 · balance_after: Includes 1,000 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in a series of two successive annual installments with the next installment occurring on January 2, 2018, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. F4 · balance_after: Includes 12,151 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in a series of three successive annual installments with the next installment occurring on January 4, 2018, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. Read SEC document
July 03, 2017 Filed Jul 5, 2017 20:08 UTC	R1 RCM Holdco Inc. RCM · Entity 125898	GrantDirector Stock Option (right to buy) · Derivative	9,678	$1.55 Strike: $3.55	$15,000.90	Disclosure SEC source: 0001472595-17-000078 · wf-form4_149928530061640.xml · derivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,678 Underlying: Common Stock · 9,678 shares Expires 2027-07-03 F1 · price: This option was issued to the reporting person pursuant to the R1 RCM Inc. director compensation plan in lieu of retainer fees of $15,000. Read SEC document
June 14, 2017 Filed Jun 15, 2017 19:27 UTC	SeaSpine Holdings Corp SPNE · Entity 120832	GrantCommon Stock	15,121	$0.00	$0.00	Disclosure SEC source: 0001637761-17-000127 · wf-form4_149755481155574.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,024 F1 · shares: The restricted stock award vests in four equal installments on each of September 14, 2017, December 14, 2017, March 14, 2018 and June 14, 2018, subject to the Reporting Person's continued service on the board of directors of SeaSpine Holdings Corporation ("SeaSpine") through each vesting date. F2 · balance_after: On July 1, 2015, Integra LifeSciences Holdings Corporation ("Integra") distributed 100% of the shares of common stock of SeaSpine that it owned to Integra stockholders of record as of the close of businesson June 19, 2015. The distribution was made to the stockholders of Integra on a pro rata basis by means of a share dividend. Integra distributed to its stockholders one share of SeaSpine common stock for everythree shares of Integra common stock held by stockholders of Integra as of the close of business on June 19, 2015. The distribution of SeaSpine shares was exempt from Section 16 of the Exchange Act by Rule16a-9. Includes 8,893 shares of SeaSpine issued to the Reporting Person pursuant to the distribution in respect of shares of Integra held by him prior to the distribution. Read SEC document
April 03, 2017 Filed Apr 5, 2017 21:33 UTC	R1 RCM Holdco Inc. RCM · Entity 125898	GrantDirector Stock Option (right to buy) · Derivative	10,512	$1.43 Strike: $3.08	$15,000.62	Disclosure SEC source: 0001472595-17-000036 · wf-form4_149142801543680.xml · derivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,512 Underlying: Common Stock · 10,512 shares Expires 2027-04-03 F1 · price: This option was issued to the reporting person pursuant to the R1 RCM Inc. director compensation plan in lieu of retainer fees of $15,000. Read SEC document
January 04, 2017 Filed Jan 5, 2017 18:29 UTC	LUMOS PHARMA, INC. (NLNK) · Entity 85102	Tax withholdingCommon Stock	1,323	$11.04	$14,605.92	Disclosure SEC source: 0001126234-17-000010 · wf-form4_148365894486994.xml · nonDerivative · entry 2 HENNEMAN JOHN B III · CIK 0001187572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,612 F5 · shares: Represents shares of Common Stock withheld by the Issuer in satisfaction of its tax withholding obligation with respect to the vesting of 4,050 previously reported RSUs granted to the Reporting Person. F2 · balance_after: Includes 20,395 RSUs previously reported as holdings of the Reporting Person granted under the Issuer's 2009 Equity Incentive Plan (the "Plan"). The RSUs will vest, and shares will be delivered to the Reporting Person in a series of two successive annual installments with the next installment occurring on October 1, 2017, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. F3 · balance_after: Includes 1,000 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in a series of two successive annual installments with the next installment occurring on January 2, 2018, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. F4 · balance_after: Includes 12,151 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in a series of three successive annual installments with the next installment occurring on January 4, 2018, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. Read SEC document
January 03, 2017 Filed Jan 4, 2017 21:25 UTC	R1 RCM Holdco Inc. ACHI · Entity 125898	GrantDirector Stock Option (right to buy) · Derivative	14,098	$1.06 Strike: $2.29	$15,000.27	Disclosure SEC source: 0001472595-17-000002 · wf-form4_148356512909976.xml · derivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,098 Underlying: Common Stock · 14,098 shares Expires 2027-01-03 F1 · price: This option was issued to the reporting person pursuant to the Accretive Health director compensation plan in lieu of retainer fees of $15,000. Read SEC document
January 03, 2017 Filed Jan 5, 2017 18:29 UTC	LUMOS PHARMA, INC. (NLNK) · Entity 85102	GrantStock Option (Right to Buy) · Derivative	137,500	$0.00 Strike: $10.55	$0.00	Disclosure SEC source: 0001126234-17-000010 · wf-form4_148365894486994.xml · derivative · entry 3 HENNEMAN JOHN B III · CIK 0001187572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,500 Underlying: Common Stock · 137,500 shares Expires not disclosed F6 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Plan on January 3, 2017 (the "Date of Grant"). 50% of the option vests and becomes exercisable in a series of 48 successive equal monthly installments beginning on February 3, 2017, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. The option expires ten years after the Date of Grant. F7 · derivative.exercise_date: The remaining 50% of the stock options vest and become exercisable as follows: (i) 12.50% upon completion of current planned Phase 1 equivalency study of new Indoximod salt formulation with "completion" measured by the last patient enrolled in such study, (ii) 12.50% upon completion of the current planned Phase 1 study of pro-Indoximod new chemical entity with "completion" measured by the last patient enrolled in such study, (iii) 12.50% upon an increase of closing share price on Nasdaq Stock Market ("Nasdaq") by at least 33% above exercise price of the options when measured over 30 consecutive calendar days, provided such increase occurs within four years of Date of Grant, otherwise such options shall be cancelled, and (iv)12.50% upon an increase of closing share price on Nasdaq by at least 50% above exercise price of the options when measured over 30 consecutive calendar days provided such increase occurs within four years of Date of Grant, otherwise such options shall be cancelled. F8 · derivative.expiration_date: Unless otherwise disclosed, the option expires ten years after the Date of Grant. Read SEC document
January 03, 2017 Filed Jan 5, 2017 18:29 UTC	LUMOS PHARMA, INC. (NLNK) · Entity 85102	Tax withholdingCommon Stock	164	$10.28	$1,685.92	Disclosure SEC source: 0001126234-17-000010 · wf-form4_148365894486994.xml · nonDerivative · entry 1 HENNEMAN JOHN B III · CIK 0001187572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,935 F1 · shares: Represents shares of Common Stock withheld by the Issuer in satisfaction of its tax withholding obligation with respect to the vesting of 500 previously reported restricted stock units ("RSUs") granted to the Reporting Person. F2 · balance_after: Includes 20,395 RSUs previously reported as holdings of the Reporting Person granted under the Issuer's 2009 Equity Incentive Plan (the "Plan"). The RSUs will vest, and shares will be delivered to the Reporting Person in a series of two successive annual installments with the next installment occurring on October 1, 2017, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. F3 · balance_after: Includes 1,000 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in a series of two successive annual installments with the next installment occurring on January 2, 2018, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. F4 · balance_after: Includes 12,151 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in a series of three successive annual installments with the next installment occurring on January 4, 2018, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.